https://doi.org/10.5812/mca-127446

Safety and Efficacy of High Protein Diet Versus GFR-based Protein Diet in Non-obese Advanced Heart Failure Patients with Renal Insufficiency: Randomized Controlled Trial Study Design

authors:

avatar Baran Hashemi ORCID 1 , avatar Seyyed Hossein Mousavi 2 , avatar Hooman Bakhshandeh ORCID 1 , avatar Sepideh Taghavi ORCID 1 , avatar Ahmad Amin ORCID 1 , avatar Majid Maleki ORCID 1 , avatar Nasim Naderi ORCID 1 , *

Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
Rajaie Cardiovascular, Medical and Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Multidisciplinary Cardiovascular Annals: Vol.13, issue 2; e127446
published online: November 23, 2022
article type: Methods Article
received: May 10, 2022
revised: May 30, 2022
accepted: July 20, 2022

How To Cite Hashemi B, Mousavi S H, Bakhshandeh H, Taghavi S, Amin A, et al. Safety and Efficacy of High Protein Diet Versus GFR-based Protein Diet in Non-obese Advanced Heart Failure Patients with Renal Insufficiency: Randomized Controlled Trial Study Design. Multidiscip Cardio Annal. 2022;13(2):e127446. https://doi.org/10.5812/mca-127446.

Abstract

Introduction:

Inadequate nutritional status has been linked to poor outcomes in heart failure patients. Generally, high protein intake is recommended for sarcopenic and malnourished patients. On the other hand, protein restriction is recommended in patients with renal damage. We found no clinical trial considering protein intake in HF patients with renal insufficiency.

Methods:

The present study is a randomized, parallel-arm, controlled pilot study. The effect of a high protein diet versus glomerular filtration rate (GFR)-based protein intake in non-obese advanced HF patients will be assessed. Muscle mass will be assessed as the main outcome. Re-hospitalization, quality of life, renal function, physical performance, appetite and mortality are the second outcomes.

Conclusions:

In the present clinical trial, for the first time, we will evaluate the effect of high protein diet in patients with advanced HF who have pre-existing renal impairment. The result of the present trial may shed light on the methods for the nutritional intervention in this group of patients.

1. Introduction

Heart failure (HF) remains a rising global epidemic with an estimated prevalence of > 37.7 million individuals globally. HF is associated with increased morbidity and mortality, and confers a substantial burden to the health-care system (1). Comorbidities include sarcopenia, renal impairment, cachexia, anemia, chronic pulmonary disease, and diabetes mellitus have been proven to be major predictors of prognosis and contribute to heart failure patients' poor quality of life (2, 3). Nutritional status and HF have strong associations (4). Individuals NYHA functional classes II and III reported a lower intake of macronutrients and micronutrients (5). Inadequate nutritional status has been linked to poor outcomes in HF patients (6, 7). Restricting protein intake may be harmful to patients with nutrition-related risk (8). Regarding the importance of good nutrition, especially adequate protein and energy intake, several trials have been conducted to demonstrate the benefits of amino acids supplementation in patients with HF. Although they have shown an improvement of exercise tolerance and, in some cases, left ventricular function, they have many limitations, namely small sample size, differences in patients’ characteristics and nutritional supplementations, and lack of data regarding outcomes (9). Furthermore, amino acid supplementation may lead to enhanced catabolic flux and exacerbate pathological remodeling and dysfunction in the post-MI hearts (10). The HF guidelines have not recommended a specific amount of protein intake (7). Generally, high protein intake is recommended for sarcopenic and malnourished patients (11, 12). On the other hand, protein restriction is recommended in patients with renal damage (13). Nonetheless, one study demonstrated that higher protein intake did not have a major impact on kidney function decline among elderly men and women (14). We found no clinical trial considering protein intake in HF patients with renal insufficiency. This study will make a meaningful difference in our knowledge about protein requirement of increasing number of HF patients.

2. Objectives

Primary Objectives: To evaluate the changes from baseline in muscle mass at 6 months of treatment for both diets

Secondary Objectives: To evaluate the changes in quality of life using Iranian heart failure quality of life questionnaire (IHF-QOL)

-To evaluate changes from baseline in Glomerular filtration rate (GFR) at 6 months of treatment for both diets

-To evaluate appetite using Simplified Nutritional Appetite Questionnaire (SNAQ)

-To evaluate changes from baseline in gait speed (timed 4-metre walk), sit-to-stand time (timed test of five chair rises), and standing balance (side-by-side stand, tandem and semi-tandem positions) at 6 months of treatment for both diets

-To evaluate changes from baseline in handgrip strength using handgrip dynamometer at 6 months of treatment for both diets

-To assess re-hospitalization frequency at 6 months of treatment for both diets

-To assess mortality rate at one year of treatment for both diets

As the primary outcome, we will look at the effect of protein consumption on muscle mass. Re-hospitalization, quality of life, physical performance, renal function, appetite and mortality are second endpoints.

3. Methods

3.1. Study Design

A randomized, parallel-arm, controlled pilot study is designed. Sample size is considered 50 participants per treatment arm (Figure 1). After baseline assessments, balanced permuted block method will be used for randomization. Concealment of the randomization sequence will be performed by the RCT center of Rajaie Cardiovascular, Medical and Research Center. Intervention will be according to the randomization sequence.

Flow diagram of the progress through the phases of the randomized trial of two groups (enrollment, intervention allocation, follow-up, and data analysis)
Flow diagram of the progress through the phases of the randomized trial of two groups (enrollment, intervention allocation, follow-up, and data analysis)
Figure 1.

Flow diagram of the progress through the phases of the randomized trial of two groups (enrollment, intervention allocation, follow-up, and data analysis)

Following examinations will be performed for each patient at the beginning and after six months.

•To assess the efficacy of protein intake on the percentage of muscle mass that will be measured by Dual-Energy X-Ray Absorptiometry (DEXA).

•To assess efficacy of protein intake on physical performance that will be measured by Short Physical Performance Battery (SPPB).

•To determine the safety of protein intake on GFR rate that will be measured by gamma counter.

Following examinations will be performed for each patient at the beginning and after one year.

•To compare the number of readmission between high protein diet and GFR based protein diet groups.

•To compare the percentage of mortality rate between high protein diet and GFR based protein diet groups.

3.2. Subject Selection

Non-obese adult HF patients with a diagnosis of advanced heart failure (stage D) according to the American and European heart failure guidelines in New York Heart Association (NYHA) class of III (3), who are under observation and management of heart failure in transplantation department of Rajaie Cardiovascular Medical and Research Center will be included in the study. Other criteria for participant selection will be glomerular filtration rate (GFR) 30 - 90, hand grip strength less than normal for age (15), and muscle mass >2 SDs below mean in individuals aged 18 - 39 years in the NHANES III cohort (2).

Subjects with respiratory failure, ventilator dependent, sepsis, dialysis treatment, open abdominal surgery within 6 weeks prior to enrolment, and disorders or conditions that might change the calorie and macronutrients requirement will be excluded from the study.

3.3. Subject Recruitment

3.3.1. Randomization

A randomized, parallel-arm, controlled preliminary study is designed. After baseline assessments, patients who are eligible to receive both diets and sign the informed consent will be recruited for the study. Balanced permuted block method will be used for randomization. Sample number is 4 in each block. Randomization will be performed by a software in RHC which generates sequences of random digits. Allocation will be equal between treatment arms which will be performed by one of the staff via software. Concealment of the randomization sequence will be performed by the RCT center of Rajaie Cardiovascular, Medical and Research Center. Participants and care providers are not blinded to the process.

3.4. Trial Intervention

3.4.1. General Information

The individualized diet including 6 - 8 small meals will be formulated by a dietitian. For each participant, weighed food records of 3 consecutive days will be analyzed for the estimation of calorie and macronutrient intake and dietary preferences. Nutritionists-4 software (16) will be used for calorie and macronutrient intake analysis.

Study participants will be allocated to receive either a high protein diet as recommended to preserve muscle mass (1.2 - 1.5 g/kg IBW) (17) or GFR based protein intake for 24 weeks (18). As required, oral nutrition support (ONS) will be considered to meet calorie and protein needs. In subjects with lower intake of protein, polyunsaturated fat will be substituted. Nutritional interaction of prescribed drugs will be considered in diet planning for each subject individually. All patients will be educated for salt and fluid intake. Diets were tailored to each patient's eating habits and preferences in order to ensure good compliance. Patients have also received two 30-minute small group sessions and two 15 - 20-minute private counseling sessions with a dietitian through video conferences.

Before initiating intervention, individuals will be assessed for anemia and electrolytes status. Any insufficiency or imbalance will be corrected by drug therapy or supplementation.

Follow up duration will be at month 3 and 6 for outcomes other than mortality. Data for mortality will be collected in one year from the beginning of the intervention. Patients will be reminded via text massage the day before each follow-up appointment. If someone does not show up for a visit, a member of the RCT staff will call her/him, a designated friend, or a family member. A heart failure specialist will supervise the whole process of the study.

3.4.2. Measurements

Baseline data will be gathered on demographic and clinical characteristics, medical history, treatments and medications. All laboratory, anthropometric and questionnaire based assessments will be performed at baseline and 3 and 6 months’ follow-up.

3.4.3. Laboratory Measures

Routine laboratory tests for heart failure patients at RHC, including complete blood count (CBC), electrolytes status, lactate, blood urea nitrogen (BUN), creatinine, uric acid, ferritin, B-type natriuretic peptide (BNP) or ProBNP, HbA1C, thyroid function, albumin and urine analysis, will be measured using standard laboratory methods.

3.4.4. Anthropometric Measures, and Sarcopenia

Anthropometric measurements will be weight (digital weight scale, Seca), height (Portable Stadiometer- Seca) and hip and waist circumference (Ergonomic Circumference Measuring Tape, Seca). For sarcopenia, body composition, muscle mass, hand grip strength and short physical performance battery (SPPB) (19) will be assessed. Total body composition and percentage of body fat as well as fat free mass for arms, legs and trunk as well as abdominal obesity will be assessed using dual-energy X-Ray absorptiometry ((DEXA), Hologic). Handgrip strength will be assessed by hand dynamometer (JAMAR® Hand Dynamometer). SPPB including gait speed (timed 4-metre walk), sit-to-stand time (timed test of five chair rises), and standing balance (side-by-side stand, tandem and semi-tandem positions) (20) will measure physical performance.

3.4.5. Kidney Function

To assess kidney function at baseline and the end of the study, urine analysis, BUN and serum creatinine assessment (colorimetric assay) as well as glomerular filtration rate (GFR) estimation (WIZARD® Automatic Gamma Counter) (21) will be performed.

3.4.6. Questionnaire-based Assessment

Appetite assessment will be performed using Simplified Nutritional Appetite Questionnaire (SNAQ) (22). This 4-item instrument has been validated in older adults and its psychometric properties evaluated in HF patients (23). This self-assessment tool measures appetite, satiety, taste of food and number of meals per day. Total score ranges from 4 to 20 and cutoff value equal or less than 14 is considered malnutrition. For quality of life, Iranian heart failure quality of life questionnaire will be used (24). A qualified staff member will complete this questionnaire. Assessment will be performed at baseline and end of the follow-up.

3.4.7. Laboratory Markers

Laboratory markers will be measured using standard methods. CBC, electrolytes, albumin, lactate, uric acid, BUN and creatinine using colorimetric assay. BNP or ProBNP, thyroid hormones and ferritin, using ELISA, and HbA1C using HPLC, (chemiluminescent immunoassay).

3.5. Data Handling and Record Keeping

Data will be collected and recorded by trained staffs in two forms of hard copy documents and electronic program which is developed in RHC. Data quality will be assessed by double entry in a software.

3.6. Statistics

3.6.1. Sample Size

Because effect size could not be confidently predicted in the absence of relevant data, sample size was not determined statistically using standard power analysis methods. This is a preliminary, exploratory study and due to resource limitation, 100 participants (in two equal groups) will be recruited.

3.6.2. Statistical Methods

Data will be described as mean ± SD for normally distributed interval, median (inter-quartile range) for skewed interval and frequency (percentage) for categorical variables. Comparisons between two groups for the interval study endpoints and their changes will be performed via independent sample t-test and repeated measure analysis of variance models and their non-parametric equivalents, including: Mann Whitney U and Friedman’s tests. Binary endpoints will be compared using Pearson’s chi square test. P value < 0.05 will be considered statistically significant.

3.6.3. Statistical Software

Data handling will be performed using MS Excel software. Statistical analysis will be conducted via IBM SPSS Statistics 22 for Windows (IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp. NY, USA).

3.7. Ethics Committee Approval

The study protocol and informed consent document have been approved by the ethics committee of Rajaie Cardiovascular Medical and Research Center (ethics code: IR.IUMS.FMD.REC.1399.660). The study protocol has also been registered and approved by clinicaltrial.gov with a code number of NCT03213821. For all study participants the purpose and procedures of the study will be explained and a written informed consent will be provided before entering the study.

4. Discussion

There is a lack of evidence about the effect of high protein diet in patients with advanced HF and uremia. However, in isolated uremia (without concomitant HF) high protein diet does not seem to worsen GFR (14). In addition, some studies showed the therapeutic effects of protein/amino acid supplementation on improving heart failure, symptoms and quality of life in HF patients without uremia (25, 26). Our hypothesis is that in individuals with advanced HF, pre-existing renal impairment (a prevalent comorbidity) affects the therapeutic benefits of a high-protein diet.

Acknowledgements

References

  • 1.

    Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13(6):368-78. [PubMed ID: 26935038]. [PubMed Central ID: PMC4868779]. https://doi.org/10.1038/nrcardio.2016.25.

  • 2.

    Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137-46. [PubMed ID: 17699180]. [PubMed Central ID: PMC1955040]. https://doi.org/10.1136/hrt.2003.025270.

  • 3.

    Muscaritoli M, Anker SD, Argilés J, Aversa Z, Bauer JM, Biolo G, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr. 2010;29(2):154-9. [PubMed ID: 20060626]. https://doi.org/10.1016/j.clnu.2009.12.004.

  • 4.

    Rahman A, Jafry S, Jeejeebhoy K, Nagpal AD, Pisani B, Agarwala R. Malnutrition and Cachexia in Heart Failure. JPEN J Parenter Enteral Nutr. 2016;40(4):475-86. [PubMed ID: 25634161]. https://doi.org/10.1177/0148607114566854.

  • 5.

    Grossniklaus DA, O'Brien MC, Clark PC, Dunbar SB. Nutrient intake in heart failure patients. J Cardiovasc Nurs. 2008;23(4):357-63. [PubMed ID: 18596500]. [PubMed Central ID: PMC4264831]. https://doi.org/10.1097/01.JCN.0000317433.52210.e0.

  • 6.

    Saitoh M, Dos Santos MR, Ebner N, Emami A, Konishi M, Ishida J, et al. Nutritional status and its effects on muscle wasting in patients with chronic heart failure: insights from Studies Investigating Co-morbidities Aggravating Heart Failure. Wien Klin Wochenschr. 2016;128(Suppl 7):497-504. [PubMed ID: 27853883]. https://doi.org/10.1007/s00508-016-1112-8.

  • 7.

    Sciatti E, Lombardi C, Ravera A, Vizzardi E, Bonadei I, Carubelli V, et al. Nutritional Deficiency in Patients with Heart Failure. Nutrients. 2016;8(7). [PubMed ID: 27455314]. [PubMed Central ID: PMC4963918]. https://doi.org/10.3390/nu8070442.

  • 8.

    Kiuchi A, Ohashi Y, Tai R, Aoki T, Mizuiri S, Ogura T, et al. Association between Low Dietary Protein Intake and Geriatric Nutrition Risk Index in Patients with Chronic Kidney Disease: A Retrospective Single-Center Cohort Study. Nutrients. 2016;8(10). [PubMed ID: 27782097]. [PubMed Central ID: PMC5084048]. https://doi.org/10.3390/nu8100662.

  • 9.

    Carubelli V, Castrini AI, Lazzarini V, Gheorghiade M, Metra M, Lombardi C. Amino acids and derivatives, a new treatment of chronic heart failure? Heart Fail Rev. 2015;20(1):39-51. [PubMed ID: 24925377]. https://doi.org/10.1007/s10741-014-9436-9.

  • 10.

    Sun H, Wang Y. Branched chain amino acid metabolic reprogramming in heart failure. Biochim Biophys Acta. 2016;1862(12):2270-5. [PubMed ID: 27639835]. https://doi.org/10.1016/j.bbadis.2016.09.009.

  • 11.

    Anker SD, Morley JE. Cachexia: a nutritional syndrome? J Cachexia Sarcopenia Muscle. 2015;6(4):269-71. [PubMed ID: 26675043]. [PubMed Central ID: PMC4670732]. https://doi.org/10.1002/jcsm.12088.

  • 12.

    Deutz NE, Bauer JM, Barazzoni R, Biolo G, Boirie Y, Bosy-Westphal A, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin Nutr. 2014;33(6):929-36. [PubMed ID: 24814383]. [PubMed Central ID: PMC4208946]. https://doi.org/10.1016/j.clnu.2014.04.007.

  • 13.

    Bauer J, Biolo G, Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013;14(8):542-59. [PubMed ID: 23867520]. https://doi.org/10.1016/j.jamda.2013.05.021.

  • 14.

    Beasley JM, Katz R, Shlipak M, Rifkin DE, Siscovick D, Kaplan R. Dietary protein intake and change in estimated GFR in the Cardiovascular Health Study. Nutrition. 2014;30(7-8):794-9. [PubMed ID: 24984995]. [PubMed Central ID: PMC4082792]. https://doi.org/10.1016/j.nut.2013.12.006.

  • 15.

    Bohannon RW, Peolsson A, Massy-Westropp N, Desrosiers J, Bear-Lehman J. Reference values for adult grip strength measured with a Jamar dynamometer: a descriptive meta-analysis. Physiotherapy. 2006;92(1):11-5. https://doi.org/10.1016/j.physio.2005.05.003.

  • 16.

    Kelishadi R, Gheisari A, Zare N, Farajian S, Shariatinejad K. Salt intake and the association with blood pressure in young Iranian children: first report from the middle East and north Africa. Int J Prev Med. 2013;4(4):475-83. [PubMed ID: 23671781]. [PubMed Central ID: PMC3650601].

  • 17.

    Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016;25(3):1057-73. [PubMed ID: 26092476]. [PubMed Central ID: PMC4876429]. https://doi.org/10.1177/0962280215588241.

  • 18.

    Rozentryt P, von Haehling S, Lainscak M, Nowak JU, Kalantar-Zadeh K, Polonski L, et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle. 2010;1(1):35-42. [PubMed ID: 21475692]. [PubMed Central ID: PMC3060643]. https://doi.org/10.1007/s13539-010-0008-0.

  • 19.

    Cano N, Fiaccadori E, Tesinsky P, Toigo G, Druml W; Dgem, et al. ESPEN Guidelines on Enteral Nutrition: Adult renal failure. Clin Nutr. 2006;25(2):295-310. [PubMed ID: 16697495]. https://doi.org/10.1016/j.clnu.2006.01.023.

  • 20.

    Cooper C, Fielding R, Visser M, van Loon LJ, Rolland Y, Orwoll E, et al. Tools in the assessment of sarcopenia. Calcif Tissue Int. 2013;93(3):201-10. [PubMed ID: 23842964]. [PubMed Central ID: PMC3744387]. https://doi.org/10.1007/s00223-013-9757-z.

  • 21.

    Bragadottir G, Redfors B, Ricksten SE. Assessing glomerular filtration rate (GFR) in critically ill patients with acute kidney injury--true GFR versus urinary creatinine clearance and estimating equations. Crit Care. 2013;17(3):R108. [PubMed ID: 23767877]. [PubMed Central ID: PMC4056314]. https://doi.org/10.1186/cc12777.

  • 22.

    Wilson MM, Thomas DR, Rubenstein LZ, Chibnall JT, Anderson S, Baxi A, et al. Appetite assessment: simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents. Am J Clin Nutr. 2005;82(5):1074-81. [PubMed ID: 16280441]. https://doi.org/10.1093/ajcn/82.5.1074.

  • 23.

    Andreae C, Stromberg A, Sawatzky R, Arestedt K. Psychometric Evaluation of Two Appetite Questionnaires in Patients With Heart Failure. J Card Fail. 2015;21(12):954-8. [PubMed ID: 26497759]. https://doi.org/10.1016/j.cardfail.2015.10.006.

  • 24.

    Naderi N, Bakhshandeh H, Amin A, Taghavi S, Dadashi M, Maleki M. Development and Validation of the First Iranian Questionnaire to Assess Quality of Life in Patients With Heart Failure: IHF-QoL. Res Cardiovasc Med. 2012;1(1):10-6. [PubMed ID: 25478482]. [PubMed Central ID: PMC4253883]. https://doi.org/10.5812/cardiovascmed.4186.

  • 25.

    Aquilani R, Opasich C, Gualco A, Verri M, Testa A, Pasini E, et al. Adequate energy-protein intake is not enough to improve nutritional and metabolic status in muscle-depleted patients with chronic heart failure. Eur J Heart Fail. 2008;10(11):1127-35. [PubMed ID: 18835539]. https://doi.org/10.1016/j.ejheart.2008.09.002.

  • 26.

    Wu C, Kato TS, Ji R, Zizola C, Brunjes DL, Deng Y, et al. Supplementation of l-Alanyl-l-Glutamine and Fish Oil Improves Body Composition and Quality of Life in Patients With Chronic Heart Failure. Circ Heart Fail. 2015;8(6):1077-87. [PubMed ID: 26269566]. [PubMed Central ID: PMC4802502]. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002073.